• 1. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119
• 2. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 3. Fe(iii)-mediated isomerization of α,α-diarylallylic alcohols to ketones via radical 1,2-aryl migration?
  Ziyang Deng,Changwei Chen,Sunliang Cui RSC Adv., 2016,6, 93753-93755
• 4. Fe/Fe3C@C nanoparticles encapsulated in N-doped graphene–CNTs framework as an efficient bifunctional oxygen electrocatalyst for robust rechargeable Zn–air batteries?
  Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526
• 5. Estimates of hydride ion stability in condensed systems: energy of formation and solvation in aqueous and polar-organic solvents
  Craig A. Kelly,David R. Rosseinsky Phys. Chem. Chem. Phys., 2001,3, 2086-2090

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives

Introduction to N-Me-D-Leu-OH·HCl (CAS No: 1221498-82-3)

N-Me-D-Leu-OH·HCl, with the chemical name N-methyl-D-leucine hydrochloride, is a compound of significant interest in the field of pharmaceutical chemistry and biochemistry. This compound, identified by its CAS number 1221498-82-3, has garnered attention due to its unique structural properties and potential applications in drug development and metabolic research. The presence of the hydrochloride salt form indicates its solubility in aqueous solutions, making it a valuable candidate for various biochemical assays and therapeutic formulations.

The structural composition of N-Me-D-Leu-OH·HCl includes a methyl group attached to the α-carbon of D-leucine, which is an enantiomer of the more commonly studied L-leucine. This configuration imparts distinct physicochemical properties that can influence its interactions with biological targets. The hydrochloride form (·HCl) further enhances its stability and bioavailability, making it an attractive moiety for pharmaceutical applications.

In recent years, there has been growing interest in the development of enantiopure compounds for targeted therapeutic interventions. N-Me-D-Leu-OH·HCl fits into this category, as its specific stereochemistry may confer unique pharmacological effects compared to its L-enantiomer. Research has begun to explore its potential role in modulating enzyme activities and receptor interactions, particularly in contexts where chirality plays a critical role in biological function.

One of the most compelling areas of research involving N-Me-D-Leu-OH·HCl is its potential application in peptidomimetics and protease inhibition. Peptidomimetics are synthetic analogs of natural peptides designed to mimic their biological activity while avoiding issues such as rapid degradation or immunogenicity. The modified side chain introduced by the methyl group in N-Me-D-Leu-OH·HCl can serve as a key structural element in designing peptidomimetics that exhibit enhanced binding affinity and selectivity towards specific proteases.

Recent studies have highlighted the importance of enantiopure compounds in oncology research. N-Me-D-Leu-OH·HCl has been investigated for its potential as a precursor or intermediate in the synthesis of novel anticancer agents. The unique stereochemistry of this compound may enable the development of drugs that selectively target cancer cells while minimizing side effects on healthy tissues. Preliminary computational studies suggest that the methyl group can influence the binding kinetics and thermodynamics when interacting with protein targets, potentially leading to more effective therapeutic outcomes.

The hydrochloride salt form (·HCl) of N-Me-D-Leu-OH·HCl also offers practical advantages in formulation development. Its solubility in water allows for easy incorporation into various pharmaceutical formulations, including injectables and oral suspensions. This property is particularly valuable for drugs that require precise dosing and rapid absorption into systemic circulation. Additionally, the stability provided by the hydrochloride salt ensures that the compound remains viable during storage and transportation, reducing concerns about degradation or loss of potency.

Another area where N-Me-D-Leu-OH·HCl shows promise is in metabolic research. Enantiopure compounds are essential tools for studying metabolic pathways and enzyme kinetics, as they allow researchers to differentiate between different stereoisomers that may exhibit distinct metabolic fates. The unique structure of N-Me-D-Leu-OH·HCl can serve as a probe to understand how modifications at specific positions within an amino acid sequence influence metabolic processing and cellular responses.

In conclusion, N-Me-D-Leu-OH·HCl (CAS No: 1221498-82-3) is a multifaceted compound with significant potential in pharmaceutical research and development. Its unique stereochemistry, solubility characteristics, and stability make it a valuable tool for designing peptidomimetics, developing anticancer agents, and investigating metabolic pathways. As research continues to uncover new applications for enantiopure compounds, N-Me-D-Leu-OH·HCl is poised to play a crucial role in advancing our understanding of biological processes and improving therapeutic strategies.

• 3060-46-6((2S)-4-methyl-2-(methylamino)pentanoic acid)
• 77481-28-8((R)-2-(Methylamino)pentanedioic acid)
• 6113-61-7(N-Formyl-L-leucine)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)